Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 6/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.40 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1363701 | 0.88 | CES2 (0.47) | GPR35PLA2G4AHSD17B3CES2CES1 | |
| SCHEMBL1364678 | 0.88 | CES2 (0.47) | GPR35PLA2G4AHSD17B3CES2CES1 | |
| SCHEMBL1365090 | 0.88 | CES2 (0.47) | GPR35PLA2G4AHSD17B3CES2CES1 | |
| SCHEMBL9948832 | 0.86 | GPR35 (0.49) | GPR35CA2PLA2G4AHSD17B3ELANE | |
| SCHEMBL10018136 | 0.86 | GPR35 (0.49) | GPR35CA2PLA2G4AHSD17B3ELANE | |
| SCHEMBL14645595 | 0.81 | GSK3B (0.56) | GPR35CA2PLA2G4AHSD17B3CES2 | |
| SCHEMBL14645639 | 0.81 | GSK3B (0.56) | GPR35CA2PLA2G4AHSD17B3CES2 | |
| SCHEMBL12374319 | 0.81 | GSK3B (0.56) | GPR35CA2PLA2G4AHSD17B3CES2 | |
| SCHEMBL1164781 | 0.81 | GSK3B (0.56) | GPR35CA2PLA2G4AHSD17B3CES2 | |
| Methyl Nonyl Ketone SCHEMBL407270 | 0.76 | GPR35 (0.52) | GPR35CA2PLA2G4ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | CORNING INCORPORATED | 2012-11-22 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| WO-2012012278-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | GPR35 1/4885CA2 656/4885PLA2G4A 792/4885 |
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, KDR | GPR35 1127/4885CA2 3178/4885PLA2G4A 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.